plerixafor has been researched along with tamoxifen in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Bouchez, LC; Cho, CY; Dubrovska, A; Hartung, A; Reddy, VA; Schultz, PG; Walker, JR | 1 |
1 review(s) available for plerixafor and tamoxifen
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for plerixafor and tamoxifen
Article | Year |
---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling.
Topics: Animals; Antineoplastic Agents, Hormonal; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzylamines; Breast Neoplasms; Cell Line, Tumor; Cyclams; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Neoplastic Stem Cells; Receptors, Aryl Hydrocarbon; Receptors, CXCR4; Signal Transduction; Tamoxifen; Transcriptional Activation; Transplantation, Heterologous | 2012 |